- Conditions
- Long Term Follow up Dry Eye Disease
- Interventions
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL), Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee
- Conditions
- Healthy Subjects
- Interventions
- Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg, OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Neurotrophic Keratopathy
- Interventions
- OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
- Conditions
- Dry Eye, Kerato Conjunctivitis Sicca
- Interventions
- Tyrvaya Nasal Pump
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dry Eye, Keratoconjunctivitis Sicca
- Interventions
- Nasal Guide
- Combination Product
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Edison, New Jersey • Woodland Park, New Jersey
- Conditions
- Dry Eye Disease (DED)
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 758 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more
- Conditions
- Dry Eye Disease
- Interventions
- OC-02 (simpinicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Nashville, Tennessee
- Conditions
- Sjogren's Syndrome, Dry Eye
- Interventions
- Varenicline Nasal Spray
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetic Retinopathy, Neurotrophic Keratitis
- Interventions
- Not listed
- Lead sponsor
- Medical Center Ophthalmology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas